false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Advances in B-Cell-Targeted Therapy for Lupus Neph ...
Advances in B-Cell-Targeted Therapy for Lupus Nephritis
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Pietro Canetta reviewed B-cell-targeted therapies for lupus nephritis, emphasizing that B cells contribute to disease through autoantibody production, but treatment responses and risks vary.<br /><br />Rituximab remains widely used despite negative primary outcomes in major randomized trials. The more potent anti-CD20 drug obinutuzumab showed benefit in phase 3 trials and is FDA-approved for lupus nephritis, though infections are a concern and many patients still do not achieve complete remission. Belimumab, which blocks BAFF, offers modest additional benefit, particularly in serologically active disease and patients with less proteinuria; benefit may be limited in pure class V disease or when added to cyclophosphamide. The talk also covered dual BAFF/APRIL blockade, plasma-cell-directed drugs such as daratumumab, and CD19 CAR-T therapy. Early results for the latter approaches are promising, but evidence, safety, cost, and scalability remain important limitations.<br /><br />In discussion, Canetta described frequently using combination therapy, tailored to disease severity and infection risk. He stressed that lupus treatment requires long-term adjustment, and that better ways to match individual patients to therapies are still needed.
Asset Caption
Pietro A. Canetta, MD, MS, FASN
Meta Tag
Speaker
Pietro A. Canetta
Keywords
lupus nephritis
B-cell-targeted therapy
rituximab
obinutuzumab
belimumab
BAFF blockade
CD19 CAR-T
×
Please select your language
1
English